scholarly journals Drug-Resistant Tuberculosis and Inhibition of Biosynthetic Enzymes for Polysaccharides in Mycobacterial Cell Wall

2011 ◽  
Vol 23 (130) ◽  
pp. 106-107
Author(s):  
Akihiro Ishiwata
Keyword(s):  
Cell Wall ◽  
Biosynthetic Enzymes ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Mycobacterial Cell ◽  
Mycobacterial Cell Wall

scholarly journals AN EXHAUSTIVE REVIEW ON EMERGING DRUG TARGETS OF TUBERCULOSIS WITH SPECIAL EMPHASIS ON CELL WALL SYNTHESIS

2021 ◽  
pp. 1-7
Author(s):  
SNEHAL R THAKAR ◽  
DEEPALI A BANSODE
Keyword(s):  
Cell Wall ◽  
Genetic Information ◽  
Drug Targets ◽  
Drug Candidate ◽  
Drug Resistant ◽  
Mortality And Morbidity ◽  
Mycobacterial Cell ◽  
Causes Of Mortality ◽  
Mycobacterial Cell Wall ◽  
Novel Drug

Tuberculosis (TB) is one of the top 10 causes of mortality and morbidity. Worldwide, yet, it has been over 60 years since a novel drug was introduced in market to treat the disease exclusively. Increased number of drug resistant TB cases has prompted the search for novel potent anti-TB drug. Mycobacterial cell wall has unique structure which provides integrity to the cell. The future development of new potent anti-TB drug targets is associated with the synthesis of various cell wall constituents; the structural and genetic information about mycobacterial cell wall envelope is now available. In the present review, we have focused on prospective drug targets that can be optimum triumph for successful drug candidate.

scholarly journals Delamanid and its Role in Drug-Resistant Tuberculosis

2017 ◽  
Vol 6 (1) ◽  
pp. 1449
Author(s):  
Supratik Das ◽  
Vijay Kumar Sehgal
Keyword(s):  
World Health Organisation ◽  
World Health ◽  
European Medicines Agency ◽  
Drug Resistant ◽  
Synthesis Inhibitor ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Resistance Patterns ◽  
Mdr Tb ◽  
Mycobacterial Cell Wall

The World Health Organisation estimates that one-third of the world's population are currently infected with Tuberculosis bacillus, 10% of whom will develop the disease at some point in their lifetime. Poverty-Stricken countries of Africa and Asia bear the brunt of the disease partly due to an ominous synergy between mycobacterium bacteria and HIV. The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability. The purpoe of this article is to bring forward, the various roles played by Delamanid in order to curb the problem of Multi-drug resistant Tuberculosis.

Anti-tubercular activity of some six membered heterocycle compounds

2019 ◽  
Author(s):  
Chem Int
Keyword(s):  
Infectious Disease ◽  
Cell Wall ◽  
Latent Tuberculosis ◽  
Drug Resistant ◽  
Significant Development ◽  
Tb Treatment ◽  
Modern Drug ◽  
Mycobacterial Cell Wall ◽  
Membered Heterocycle ◽  
New Chemical Entity

The effectiveness in TB treatment is difficult because the structural composition of the mycobacterial cell wall is very complicated, which makes many drugs ineffective. Tuberculosis is still one of the most imperative infectious disease worldwide becouse its important reason is drug resistant, persistent or latent tuberculosis and synergism with HIV. Furthermore no any new chemical entity has come. The recently application of modern drug design promise to bring significant development in the fight against TB. In present review we discussed brief introduction of tuberculosis.

Sign in / Sign up

Export Citation Format

Share Document